BBOT
BridgeBio Oncology Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.64
−2.37%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.69
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.71
- EPS estimate
- -$0.56
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -48.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $20
- PT range
- $13 – $27
- Analysts
- 8
8 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.56 | -$0.71 | Miss -24.81% | — |
| Jun 4, 2026 | -$0.51 | -$0.53 | Miss -2.76% | — |
| Mar 5, 2026 | -$0.42 | -$0.49 | Miss -16.67% | — |
| Nov 12, 2025 | -$0.41 | -$1.03 | Miss -151.22% | — |
| Aug 1, 2025 | — | $0.04 | — | — |
| May 15, 2025 | — | -$0.02 | — | — |
| Mar 11, 2025 | — | $0.12 | — | — |
| Nov 14, 2024 | — | $0.10 | — | — |
| Aug 14, 2024 | — | $0.09 | — | — |
| May 15, 2024 | — | $0.08 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026